Roivant Sciences Ltd.
brepocitinib
dermatomyositis
Resolved
151days ago
Catalyst readout · Feb 6, 2026
What's at stake
A key catalyst for brepocitinib (dermatomyositis) is expected Feb 6, 2026.
Primary source
· SEC 8-K
verified 13h ago
“New Drug Application (NDA) was submitted to the FDA for brepocitinib in dermatomyositis (DM).”